glp-1 kaiser What you need to know about the latest weight-loss drugs Kaiser Permanente Glp 1 2025

Borba VZC, Costa T

However, they are typically recommended as part of a comprehensive weight management plan that includes a healthy diet and regular physical activity

In 2024 the Food and Drug Administration added cardiovascular risk as a reason to be prescribed the GLP-1 drug Wegovy, grounded in results from a major trial that showed fewer heart attacks, strokes, and cardiovascular deaths in adults with obesity or overweight and established heart disease

Subsequent pursuit of additional incretins eventually led to the discovery of glucagon-like peptide 1 (GLP-1) in 1987 1416

Nearly 3 in 4 UK GLP-1 users have felt a boost in confidence since starting the medication, with women being 25% more likely than men to experience this shift

Novo Nordisk announced FDA acceptance of their New Drug Application (NDA) for a 25 mg oral version of Wegovy for two new indications: (1) chronic weight management in adults living with obesity or who are overweight with at least one comorbid condition, and (2) to reduce the risk of MACE in adults with overweight or obesity and established CVD